These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26407428)

  • 1. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
    Haber P; Moro PL; Cano M; Vellozzi C; Lewis P; Woo EJ; Broder K
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):205-13. PubMed ID: 26407428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
    Haber P; Moro PL; Cano M; Lewis P; Stewart B; Shimabukuro TT
    Vaccine; 2015 Apr; 33(16):1987-92. PubMed ID: 25678241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.
    Moro PL; Arana J; Cano M; Menschik D; Yue X; Lewis P; Haber P; Martin D; Broder K
    Clin Infect Dis; 2012 Jun; 54(11):1608-14. PubMed ID: 22441652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
    Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.
    Moro PL; Woo EJ; Marquez P; Cano M
    Vaccine; 2020 Aug; 38(37):5923-5926. PubMed ID: 32709434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events reported following live, cold-adapted, intranasal influenza vaccine.
    Izurieta HS; Haber P; Wise RP; Iskander J; Pratt D; Mink C; Chang S; Braun MM; Ball R
    JAMA; 2005 Dec; 294(21):2720-5. PubMed ID: 16333007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
    Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.
    Muhammad R; Haber P; Broder K; Leroy Z; Ball R; Braun MM; Davis RL; McMahon AW
    Pediatr Infect Dis J; 2011 Jan; 30(1):e1-8. PubMed ID: 21042229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.
    Baxter R; Eaton A; Hansen J; Aukes L; Caspard H; Ambrose CS
    Vaccine; 2017 Mar; 35(9):1254-1258. PubMed ID: 28162825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems.
    Lee H; Kim HJ; Choe YJ; Shin JY
    Vaccine; 2020 Jul; 38(34):5464-5473. PubMed ID: 32600907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.
    Bardenheier BH; Duderstadt SK; Engler RJ; McNeil MM
    Vaccine; 2016 Aug; 34(37):4406-14. PubMed ID: 27449076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
    Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.